Table of contents
- Original news
- What issues did this case raise?
- Hasn’t the CJEU already decided questions in this area before?
- Did the judge feel the CJEU had been unclear in the past
- What happens next?
- What does this mean for lawyers and the pharmaceutical industry?
Article summary
IP&IT analysis: What is the scope of a combination Supplementary Protection Certificate? A closer look at the two questions referred to the CJEU in the Sanofi case and their potential to clarify the law in this area.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial